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Abstract: The use of an herbomineral formulation in the healthcare sector for different chronic diseases is gaining popularity 
due to its fewer side-effects, high safety profile, and cost effectiveness. A new proprietary herbomineral formulation was 
formulated, consisting of four essential ingredients viz. herbal (ashwagandha root extract) and minerals (zinc chloride, magnesium 
gluconate, and sodium selenate). The objective of this study was to evaluate the immunomodulatory effect of the Biofield Energy 
Treated test formulation on female Sprague Dawley (SD) rats. The test formulation was divided into two parts; one was 
represented as control, while the other part was treated with the Biofield Energy Healing Treatment remotely by renowned 
Biofield Energy Healers (The Trivedi Effect
®
) and defined as the Biofield Energy Treated formulation. The effect of the test 
formulation was monitored using humoral immune response, delayed type hypersensitivity, hematology, biochemistry, relative 
organ weight, and histopathology. The primary hemagglutination (HA) antibody titre level was significantly (p≤0.05) increased by 
185.88% in the Biofield Energy Treated group (G3); while 41.18% increased in the untreated test formulation group (G4) as 
compared to the disease control group (G2). The secondary HA titre was significantly increased by 540% (p≤0.001) and 166.7% 
in the G3 and G4 groups, respectively as compared to the G2 group. The secondary HA titre was also increased significantly 
(p≤0.05) by 193% in the Biofield Energy Treated group per se at day -15 (G6), as compared to the G2 group. The paw volume 
data showed an alteration in the G3 and G6 groups as compared to the G2 group. The platelet count was significantly increased by 
11.16% and 8.69% in the G3 and G4 groups, respectively as compared to the G2 group. The magnesium level was increased by 
9.31% in the G3 group as compared to the G2 group. The uric acid was significantly reduced by 23.88% in the G3 group; while it 
was increased by 17.47% in the G4 group as compared to the G2 group. Since, the relative organ weight and histopathological 
findings did not produce any signs of toxicity as compared to the normal control group (G1). These data suggested that the 
Biofield Energy Treated herbomineral formulation was found to be safe and showed better immunomodulatory response as 
compared to the untreated formulation. Thus, it is assumed that the Biofield Energy Treated herbomineral formulation could be 
better and more useful to boost-up the immune system in healthy human and patients. 
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1. Introduction 
Natural products derived from plants and minerals are 
always regarded as the primary source for new herbomineral 
formulation for maintaining the overall health [1]. Medicinal 
plant-derived drugs are continuously gaining popularity in 
the developed and developing countries alike, due to their 
natural origin and less side effects. Many traditional and 
complementary medicines are derived from medicinal plants, 
minerals, and organic matter, which are commonly used for 
the prevention and treatment of many diseases [2]. According 
to World Health Organization (WHO), medicinal plants are 
always being the target of most of the pharmaceutical 
companies for new formulations [3], due to the presence of 
one or more active phytoconstituents [4]. With this aspect, a 
new proprietary herbomineral formulation was formulated 
with a combination of the herb ashwagandha root extract and 
three minerals viz. zinc chloride, magnesium gluconate, and 
sodium selenate. All the components have been reported for 
important pharmacological activities, such as ashwagandha 
(Withania somnifera) that belongs to the family Solanaceae, 
commonly used as alternative therapies [5, 6] due to the 
presence of pharmacologically active molecule like 
withanolides [7]. Apart from its common attributes such as 
antibacterial, immunomodulatory and antitumor effects, 
many clinical and preclinical data have been available with 
respect to the immunomodulatory impact [8, 9]. The 
importance of minerals such as selenium, zinc, and 
magnesium to modulate the immune system has been well-
defined [10]. The scientific research has been documented 
that due to the presence of minerals, herbal medicines have 
been found to exhibit a high level of phagocytic index and 
improved antibody titre [11]. These formulations can be used 
for better therapeutic effect in immune compromised patients 
that are affected by the cardiovascular diseases, age and 
stress related diseases, cancer, and autoimmune disorders. 
Along with the herbomineral formulations, the Biofield 
Energy Healers in this study have used Energy Medicine 
(Biofield Energy Healing Treatment) as a complementary 
and alternative approach to study the impact of Biofield 
Energy Treatment on the herbomineral formulation for its 
immunomodulatory potential in female Sprague Dawley rats. 
In recent years, several scientific reports and clinical trials 
have shown the useful effects of Biofield Energy Treatment, 
which has shown enhanced immune function in cases of 
cervical cancer patients with therapeutic touch [12], massage 
therapy [13], etc. Complementary and Alternative Medicine 
(CAM) is now rising as preferred model of treatment, among 
which Biofield Therapy (or Healing Modalities) is one 
approach that has been reported with several benefits to 
enhance the physical, mental and emotional human wellness. 
The National Center of Complementary and Integrative 
Health (NCCIH) has recognized and accepted Biofield 
Energy Healing as a Complementary and Alternative 
Medicine (CAM) health care approach in addition to other 
therapies, medicines and practices such as natural products, 
deep breathing, yoga, Tai Chi, Qi Gong, 
chiropractic/osteopathic manipulation, meditation, massage, 
special diets, homeopathy, progressive relaxation, guided 
imagery, acupressure, acupuncture, relaxation techniques, 
hypnotherapy, healing touch, movement therapy, pilates, 
rolfing structural integration, mindfulness, Ayurvedic 
medicine, traditional Chinese herbs and medicines, 
naturopathy, essential oils, aromatherapy, Reiki, and cranial 
sacral therapy. Human Biofield Energy has subtle energy that 
has the capacity to work in an effective manner [14]. 
Complementary and Alternative Medicine (CAM) therapies 
have been practiced worldwide with reported clinical benefits 
in different health disease profiles [15]. This energy can be 
harnessed and transmitted by individuals into living and non-
living things via the process of Biofield Energy Healing. 
Biofield Energy Treatment (The Trivedi Effect
®
) outcomes 
have been reported in numerous peer-reviewed science 
journals with significant outcomes in many scientific fields 
such as cancer research [16, 17], altered antimicrobial 
sensitivity of pathogenic microbes in microbiology [18-21], 
genetics [22, 23], altered physical and chemical properties of 
pharmaceutical compounds [24-27], improved overall growth 
and yield of plants in agricultural science [28-31], and 
changing the structure of the atom in relation to various 
metals, ceramics, polymers and chemicals in materials 
science [32-35]. The authors evaluated the impact of Biofield 
Energy Treatment (The Trivedi Effect
®
) on the given 
herbomineral formulation in female Sprague Dawley rats, 
which might improve the immunomodulatory function with 
respect to the antibody titre, delayed type hypersensitivity 
reaction, hematological parameters, and serum biochemistry 
using standard assays. 
2. Materials and Methods 
2.1. Chemicals and Reagents 
Pyrogallol and sodium carboxymethyl cellulose were 
purchased from Sigma Chemical Co. (St. Louis, MO). 
Ashwagandha (Withania somnifera) root extract powder was 
procured from Sanat Products Ltd., India. Zinc chloride and 
magnesium (II) gluconate hydrate were procured from TCI, 
Japan. Sodium selenate was procured from Alfa Aesar, 
U.S.A. Levamisole hydrochloride was procured from Sigma, 
U.S.A. All other chemicals used in this study were of 
analytical grade available locally. 
2.2. Laboratory Animals 
All the procedures and protocols were approved by 
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Institutional Animal Ethics Committee (IAEC). All the 
animals were handled humanely with due regard for their 
welfare. Care of animals were complied with the regulations 
of Committee for the Purpose of Control and Supervision of 
Experiments on Animals (CPCSEA), Govt. of India. 
Randomly breed healthy female Sprague Dawley rats body 
weight ranges between 132-183 grams, were used for the 
study. All the animals were housed under standard 
experimental conditions, with room temperature (22 ± 3°C) 
and relative humidity (30% to 70%). 
2.3. Biofield Energy Healing Strategies 
The herbomineral test formulation was divided into two 
parts. One part of the test formulation was treated with 
Biofield Energy by renowned Biofield Energy Healers (also 
known as The Trivedi Effect
®
) and coded as the Biofield 
Energy Treated formulation, while the second part of the test 
formulation did not receive any sort of treatment and was 
defined as the untreated test formulation. This Biofield 
Energy Treatment was provided to the test formulation 
through a group of eighteen Biofield Energy Healers who 
participated in this study and performed the Biofield Energy 
Treatment to the test formulation remotely. Eleven Biofield 
Energy Healers were remotely located in the U.S.A, four 
were remotely located in Canada, and one of which was 
remotely located in UK, Russia and Ireland, while the test 
herbomineral formulation was located in the research 
laboratory of Dabur Research Foundation, New Delhi, India. 
This Biofield Energy Treatment was administered for 5 
minutes through the Healer’s Unique Energy Transmission 
process remotely to the test formulation under the laboratory 
conditions. Besides, one group of animals was also received 
Biofield Energy Treatment per se by Biofield Energy Healers 
under similar conditions. None of the Biofield Energy 
Healers in this study visited the laboratory in person, nor had 
any contact with the herbomineral samples. Further, the 
control group was treated with a “sham” healer for 
comparative purpose. The sham healer did not have any 
knowledge about the Biofield Energy Treatment. After that, 
the Biofield Energy Treated and untreated test formulations 
were returned in the similar sealed condition and kept in 
recommended storage condition. 
2.4. Antigen (Sheep RBC) 
The fresh sheep blood was collected aseptically from the 
jugular vein of a healthy sheep and transferred immediately 
to the heparinized tube. The collected erythrocytes were 
separated from plasma by centrifugation (400 g, 10°C, 10 
minutes), washed twice with the normal saline and then 
further diluted in saline and the samples were analyzed using 
Hematology analyzer (Abbott Model-CD-3700). Based on 
the number of erythrocytes, the samples were further diluted 
(using saline) before injecting to the rat [36]. 
2.5. Experimental Procedure 
After 5 days of acclimatization, the animals were grouped 
(G) based on the body weight. G1 (normal control) received 
oral suspension of 0.5% carboxy methyl cellulose-sodium 
salt via gavage. The G2 (disease control) received pyrogallol 
at a dose of 100 mg/kg through intraperitoneal (i.p.) route 
once daily for 7 days. The G3 animals received the Biofield 
Energy Treated test formulation (1105.005 mg/kg b.wt, p.o.). 
The G4 received untreated test formulation at the same dose 
orally, while the G5 received levamisole at a dose of 50 
mg/kg p.o. from day 1 to day 22. Further, the G6 received 
Biofield Energy Treatment group per se at day -15, without 
any test formulation. All the animals except normal control 
group received pyrogallol at a dose of 100 mg/kg through i.p. 
route once daily from day 1 to 7. The animals were 
administered with the Biofield Energy Treated and untreated 
test formulation to the G3 and G4 animals, respectively, one 
hour before the pyrogallol challenge in the morning once 
daily for 22 days. The treatment was continued to all the 
tested groups (G1 to G6) with 5 mL/kg body weight dose 
volume. On day 7 and day 13, all the animals in G2-G6 
except normal control (G1) were challenged with sheep red 
blood cells (sRBC) (0.5 X 10
9
/100 gm; i.p.) as the antigenic 
material to sensitize them for immunological parameters. On 
the days 13
th
 and 20
th
, blood sample was collected from retro-
orbital plexus and subjected to hemagglutination test to 
evaluate the humoral immune response. On the same day, the 
animals were challenged with sheep RBC (0.5 x 10
9
 cells/50 
µL/rat) in sub-planter region and on 22
nd
 day (48 hours), paw 
volume was measured to evaluate cellular immune response. 
The body weight and food consumption were measured daily 
before treatment. On day 22, the animals were kept under 
fasting over night and on day 23; blood was collected again 
from retro-orbital plexus from each animal under isoflurane 
anaesthesia. Whole blood was analysed for haematological 
parameters and serum was analysed for serum biochemistry. 
At the end of the study; animals were euthanized by CO2 
asphyxiation as per in-house approved standard protocol. 
Different organs of all animals were excised, weighed and 
preserved for histopathological analysis. 
2.6. Determination of Humoral Immune Response 
On day 13 and 20, blood was withdrawn from the retro-
orbital plexus of all antigenically challenged rats. 
Approximately 25 µL of serum was serially diluted with 25 
µL of phosphate-buffered saline. The sRBC (0.025 x 10
9
 
cells) was added to each of these dilutions and incubated at 
37°C for one hour. The rank of minimum dilution that 
exhibited hemagglutination (HA) was considered as an 
antibody titre. The level of antibody titre on day 13 of the 
experiment was considered as the primary humoral immune 
response and the day 20 of the experiment was considered as 
the secondary humoral immune response [37]. 
2.7. Determination of Paw Volume (Delayed Type 
Hypersensitivity) 
The cellular immune response was assayed by the footpad 
reaction method. The edema was induced in the right paw of 
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rats by injecting sRBC (0.025 x 10
9
 cells) in the sub-plantar 
region. The change in paw volume was assessed on digital 
plethysmometer (PanLab, Spain). The mean percentage 
increase in paw volume was considered as delayed type of 
hypersensitivity as an index of cell-mediated immunity. The 
volume of the left hind paw, injected similarly with 
phosphate-buffered saline, served as control. 
2.8. Determination of Hematological and Biochemical 
Parameters 
After fasting for 12 to 16 hours on day 23
rd
 of the 
experiment, blood was collected from the retro-orbital plexus 
using heparinized and non-heparinized capillary tubes. The 
non-heparinized capillary tube of blood was kept in plain 
bottle from which serum was collected and further stored for 
biochemical analysis. The heparinized tube containing blood 
was directly subjected for the estimation of various 
hematological parameters using standard instrument. The 
various hematological parameters such as hemoglobin (Hb), 
red blood corpuscle (RBC), packed cell volume (PCV), mean 
corpuscular volume (MCV), mean corpuscular hemoglobin 
(MCH), mean corpuscular hemoglobin concentration 
(MCHC) and platelets were analyzed with blood samples. 
Further, the level of magnesium, blood urea nitrogen (BUN), 
creatinine, uric acid, calcium, phosphorus, potassium, 
sodium, and chloride ion concentration was analyzed in 
serum sample using Hematology analyzer (Abbott Model-
CD-3700) [38]. 
2.9. Determination of Body Weight and Feed Intake 
Body weight and feed intake of all the animals in various 
experimental groups were measured once daily before 
dosing. Briefly, the weight of daily feed supply and the left-
over by the following day was recorded and the difference 
was taken as the daily feed intake. The average feed intake 
was computed for every three days of the experimental 
period [39]. 
2.10. Clinical Sign and Symptoms 
All the animals were observed for the clinical signs and 
symptoms once daily in accordance with the in-house 
protocol [40]. Animals found in a moribund condition or 
enduring signs of severe distress was humanely euthanized. 
Abnormal findings were recorded with the time of onset and 
disappearance. 
2.11. Measurement of Relative Organ Weight and 
Histopathology 
At the end of the experiment, rats were dissected and 
the whole liver, kidneys, hearts, spleens, lungs, whole 
intestine, eyes, brain, and ovaries were excised, freed of 
fat, blotted with clean tissue paper, and then weighed. The 
organ to body weight ratio was determined by comparing 
the weight of each organ with the final body weight of 
each rat. Defined samples were placed in 10% neutral 
buffered formalin for histopathological examination as per 
standard protocol. 
2.12. Statistical Analysis 
Data were expressed as mean ± standard error of mean 
(S.E.M.) and were subjected to one-way analysis of variance 
(ANOVA) followed by Dunnett’s multiple range test and 
Student’s t-test. Statistical significance was considered at 
p<0.05. 
3. Results and Discussion 
3.1. Determination of Humoral Immune Response 
The results of primary and secondary humoral immune 
responses after oral administration of test formulation in 
female Sprague Dawley rats are summarized in the Table 
1. The primary mean hemagglutination (HA) antibody titre 
level was significantly (p≤0.05) increased by 185.88% and 
41.18% in the Biofield Energy Treated test formulation 
group and the untreated test formulation group, 
respectively as compared to the disease control group. It 
indicated that the Biofield Energy Treated test formulation 
showed better response in comparison with the untreated 
test formulation group. It is assumed that the increased 
level of primary HA titre in the Biofield Energy Treated 
test formulation might be due to Biofield Energy Healing 
(The Trivedi Effect
®
) through Biofield Energy 
Transmission to the test formulation. The primary HA titre 
response was increased by 17.65% in the levamisole 
(reference item) group as compared to the disease control 
group. The response of the primary HA titre was 
decreased by 55.29% in the Biofield Energy Treated group 
per se at day -15 as compared to the disease control group. 
On day 20
th
, the secondary immune response of mean HA 
titre level was significantly increased by 540% (p≤0.001) 
and 166.7% in the Biofield Energy Treated test 
formulation group and the untreated test formulation 
group, respectively as compared to the disease control 
group. It indicated that there was an improvement of 
secondary HA titre in the Biofield Energy Treated test 
formulation than the untreated test formulation. The level 
of secondary HA titre was also increased significantly by 
260% (p≤0.001) and 193% (p≤0.05) in the levamisole and 
the Biofield Energy Treated group per se at day -15, 
respectively as compared to the disease control group. 
Kawai et al. reported that the primary and secondary 
responses observed through the stimulation of the T-cell-
dependent antigen [41]. Based on this, it is presumed that 
the Biofield Energy Treated herbomineral formulation 
shows the potential immunomodulatory activities which 
could be due to the T-cell-dependent antigen response. 
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Table 1. The effect of the test formulation on primary and secondary humoral immune response in female Sprague Dawley rats. 
Group Primary HA titre Secondary HA titre 
Disease control 8.50 ± 3.35 10.00 ± 0.00 
Biofield Treated formulation 24.30 ± 8.83* 64.00 ± 0.00*** 
Untreated test formulation 12.00 ± 1.79 26.67 ± 3.37 
Reference item (Levamisole) 10.00 ± 0.00 36.00 ± 9.63*** 
Biofield Treated group per se at day -15 3.80 ± 0.98 29.30 ± 7.64* 
HA: Hemagglutination assay. All the values are expressed as the mean ± SEM. *p≤0.05 and ***p≤0.001 as compared to the disease control. 
3.2. Effect of the Test Formulation on Paw Volume 
(Delayed Type Hypersensitivity) 
The effects of the Biofield Energy Treated and the 
untreated test formulations on delayed type hypersensitivity 
response (DTH) are shown in the Figure 1. The levamisole 
group (G5) showed significantly (p<0.01) increased in paw 
volume as compared to the disease control group (G2). The 
paw volume was altered in the Biofield Energy Treated test 
formulation (G3), untreated test formulation (G4), and the 
Biofield Energy Treatment group per se at day -15 (G6) as 
compared to the disease control group (G2). 
 
Figure 1. Effect of the test formulation on paw volume (delayed-type 
hypersensitivity) in female Sprague Dawley rats. G1: Normal control; G2: 
Disease control; G3: Biofield Energy Treated test formulation; G4: 
Untreated test formulation; G5: Reference item (Levamisole); G6: Biofield 
Energy Treated group per se at day -15. All values are expressed as the mean 
± SEM (n = 6). **p≤0.01 vs disease control. 
3.3. Determination of Hematological Parameters 
Various studies on nutraceutical supplementation have 
demonstrated the quality with respect to the body mass, 
reproductive timing and sociality [42, 43]; however, plenty of 
studies evaluated effects of supplementation on hematologic 
and immunologic parameters [44]. The effect of the Biofield 
Energy Treated proprietary nutraceutical product on various 
hematological parameters is presented in the Table 2. The 
level of red blood corpuscle (RBC) in the disease control 
group (G2) was reduced by 8.94% as compared to the normal 
control group (G1). Besides, the level of RBC was 
significantly increased by 3.41%, 6.26%, 4.98%, and 9.39%, 
in the Biofield Energy Treated test formulation (G3), 
untreated test formulation (G4), levamisole (G5), and 
Biofield Energy Treated group per se at day -15 (G6), 
respectively as compared to the disease control group (G2). It 
is assumed that this improvement could be due to the 
influence of Biofield Energy Healing through Biofield 
Energy Healers. The level of hemoglobin (Hb) was not 
altered in all the tested groups as compared to the both 
normal (G1) as well as disease control (G2) groups. The 
platelet count was significantly decreased by 5.34% in the 
disease control group (G2) as compared to the normal control 
(G1). 
Further, the platelet count was significantly increased by 
11.16% in the Biofield Energy Treated test formulation group 
(G3) with respect to the disease control (G2). While the 
platelet count was significantly decreased by 8.69% in the 
untreated test formulation group (G4) with respect to the 
disease control (G2). There was an improvement of platelets 
counts in the G3 group as compared to the G4 group. This 
increased number of platelet counts in the Biofield Energy 
Treated formulation might be due to the influence of Biofield 
Energy Healing on herbomineral formulation. Besides, there 
was an elevation of platelets by 13.58% in the Biofield 
Energy Treated group per se at day -15 (G6); while it was 
altered in the levamisole group as compared to the disease 
control (G2). In the literature, it was reported that 
ashwagandha prevented myelosuppression and increase in 
platelet count and body weight [45]. Our experimental 
finding like increased platelet count was well corroborated 
with the literature observation due to the presence of 
ashwagandha as one of the components in the proprietary 
formulation. Among other hematological parameters like 
packed cell volume (PCV) was significantly increased by 
9.70% in the Biofield Energy Treated group per se at day -15 
(G6) as compared to the disease control (G2). However, the 
PCV did not alter in the other groups as compared to the both 
normal as well as disease control groups. 
Moreover, the level of mean corpuscular volume (MCV) 
was also increased by 8.24% in the disease control (G2) as 
compared to the normal control (G1). The level of MCV was 
reduced in all the tested groups except in the Biofield Energy 
Treated group per se at day -15 (G6) as compared to the 
disease control (G2). Additionally, the level of red cell 
distribution width - Coefficient of Variation (RDW-CV) was 
increased by 13.33% in the disease control (G2) as compared 
to the normal control group (G1). However, the value of 
RDW-CV was reduced in the Biofield Energy Treated test 
formulation (G3), untreated test formulation (G4) and 
levamisole group (G5); while the value was similar in the 
Biofield Energy Treated group per se at day -15 (G6) as 
compared to the disease control (G2). It was reported that W. 
somnifera extract was non-toxic to human erythrocytes at 
different concentrations [46]. Our experimental results also 
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suggested that the test formulation did not have any toxic 
effect on RBC, as no significant change was observed in 
different groups with respect to both the normal control and 
disease control groups. Besides, the minerals present in the 
test formulation were found to be safe, along with good 
therapeutic effect [47]. 
Table 2. Evaluation of hematology parameters assessed after Biofield Energy Treatment on the test formulation in female Sprague Dawley rats. 
Group 
RBC 
(106/	L) 
Hb 
(gm/dL) 
PCV 
(%) 
MCV 
(fl) 
MCH 
(pg) 
MCHC 
(%) 
Platelet Count 
(thousand/mm3) 
RDW-CV 
G1 7.72 ± 0.23 14.90 ± 0.55 43.52 ± 1.42 56.40 ± 1.11 19.28 ± 0.38 34.23 ± 0.25 1047.50 ± 113.10 0.13 ± 0.00 
G2 7.03 ± 0.15 15.20 ± 0.18 42.87 ± 0.58 61.05 ± 0.72 21.67 ± 0.55 35.48 ± 0.48 991.67 ± 52.01 0.15 ± 0.01 
G3 7.27 ± 0.11 14.33 ± 0.18 42.17 ± 0.54 58.10 ± 0.86 19.72 ± 0.26 34.00 ± 0.06 1102.33 ± 24.50 0.14 ± 0.00 
G4 7.47 ± 0.19 14.70 ± 0.40 43.02 ± 1.21 57.70 ± 1.00 19.73 ± 0.42 34.15 ± 0.34 905.50 ± 162.29 0.14 ± 0.00 
G5 7.38 ± 0.40 15.25 ± 0.94 44.12 ± 2.31 59.90 ± 3.75 20.72 ± 1.30 34.55 ± 0.96 996.17 ± 136.43 0.14 ± 0.01 
G6 7.69 ± 0.11 15.78 ± 0.33 47.03 ± 1.01 61.18 ± 0.71 20.53 ± 0.24 33.55 ± 0.13 1126.33 ± 46.76 0.15 ± 0.00 
G1: Normal control; G2: Disease control; G3: Biofield Energy Treated test formulation; G4: Untreated test formulation; G5: Reference item (Levamisole); G6: 
Biofield Energy Treated group per se at day -15. Hb: Hemoglobin; RBC: Red blood count; PCV: Packed cell volume; MCV: Mean corpuscular volume; MCH: 
Mean corpuscular hemoglobin; MCHC: Mean corpuscular hemoglobin concentration; Red cell distribution width and volume (RDW-CV). 
3.4. Evaluation of Biochemical Parameters 
The effect of the Biofield Energy Treated test formulation 
on different biochemical parameters is shown in the Table 3. 
The level of magnesium was increased by 9.31% in the 
Biofield Energy Treated test formulation group (G3) as 
compared to the disease control (G2). In rest of the groups 
(G4 to G6), results showed an alteration of magnesium as 
compared to the disease control (G2). Thus, the improvement 
of magnesium concentration in the Biofield Energy Treated 
test formulation could be fruitful to the patients those who 
are suffering from the deficiency of magnesium. Moreover, 
the serum concentration of uric acid (UA) was 2.85 ± 0.37 
mg/dL in the normal control group and it was significantly 
increased by 16.49% in the disease control group (3.32 ± 
0.30 mg/dL). Further, the concentration of UA was 
significantly reduced by 23.88% in the Biofield Energy 
Treated test formulation (G3); however it was increased in 
the untreated test formulation (G4) by 17.47% with respect to 
the disease control (G2). Here, the Biofield Energy Treated 
herbomineral formulation showed beneficial effect by 
reducing the concentration of UA than the untreated product. 
The results might be due to the positive effect of Biofield 
Energy Healing to the novel herbomineral product, which 
could be very helpful in the patients with autoimmune 
disorders like rheumatic arthritis and psoriasis in near future. 
Besides, the levels of blood urea, creatinine, calcium, 
phosphorous, and ions like sodium, potassium, and chloride 
were altered in all the experimental groups to some extent but 
did not show any significant difference with respect to the 
disease control group. Altogether, on the assessment of 
serum biochemistry profile, there was a significant elevation 
in the level of serum magnesium and significant reduction of 
UA in the Biofield Energy Treated test formulation (G3) as 
compared to the disease control (G2). The siginificant 
outcomes of Biofield Energy Healing on the herbomineral 
formulation might be due to the electromagnetic field or 
radiations of Healers during energy transmission process. 
Table 3. Assessment of the Biofield Energy Treated and the untreated test formulations on biochemical parameters in female Sprague Dawley rats. 
Group 
Magnesium 
(mg/dL) 
Blood Urea 
(mg/dL) 
Creatinine 
(mg/dL) 
Uric Acid 
(mg/dL) 
Calcium 
(mg/dL) 
Phosphorus 
(mg/dL) 
Na+ (Meq/L) K+ (mEq/L) Cl- (mEq/L) 
G1 2.61 ± 0.08 39.37 ± 2.25 0.60 ± 0.00 2.85 ± 0.37 10.02 ± 0.14 8.00 ± 0.20 142.37 ± 7.48 5.15 ± 0.09 102.17 ± 0.17 
G2 2.90 ± 0.07 47.30 ± 3.61 0.58 ± 0.03 3.32 ± 0.30 10.30 ± 0.17 8.93 ± 0.31 150.17 ± 0.54 5.38 ± 0.07 103.67 ± 0.61 
G3 3.17 ± 0.13 46.32 ± 2.61 55 ± 00.06 2.68 ± 0.15 10.15 ± 0.21 8.97 ± 0.21 151.17 ± 0.70 4.97 ± 0.11 102.17 ± 1.01 
G4 3.51 ± 0.14 53.02 ± 2.57 0.62 ± 0.05 3.90 ± 0.40 10.60 ± 0.18 10.33 ± 0.30 150.00 ± 0.63 5.53 ± 0.22 102.50 ± 0.56 
G5 3.02 ± 0.16 51.52 ± 3.32 0.68 ± 0.10 0.68 ± 0.10*** 10.73 ± 0.17 9.08 ± 0.24 151.00 ± 0.68 5.40 ± 0.17 104.67 ± 0.61 
G6 2.93 ± 0.20 43.00 ± 2.18 0.52 ± 0.02 3.18 ± 0.46 10.42 ± 0.22 9.20 ± 0.42 150.00 ± 0.22 5.53 ± 0.22 103.83 ± 0.70 
G1: Normal control; G2: Disease control; G3: Biofield Energy Treated test formulation; G4: Untreated test formulation; G5: Reference item (Levamisole); G6: 
Biofield Energy Treated group per se at day -15. The values are represented as mean ± SEM of 6 animals in each group. ***p≤0.001 (as compared to the disease 
control group). 
3.5. Analysis of Body Weight, Feed Intake, and Relative 
Organ Weight ratio (Percentage) 
The Biofield Energy Treated test formulation group (G3) 
showed consistent improvement of the both feed intake and 
body weight throughout the experiment. The absolute weight 
of various vital organs such as liver, lungs, kidneys, brain, 
heart, eyes, spleen, whole intestine, and ovaries were 
recorded at the end of the experiment as per standard 
protocol. From this, based on the final body weight (on day 
22), the relative organ weight ratio (as percentage) was 
calculated in all the groups and the data is shown in the Table 
4. Overall, results showed that the Biofield Energy Treated 
formulation (G3), untreated test formulation (G4), and 
Biofield Energy Treatment group per se at day -15 (G6) did 
not produce any signs of toxicity as compared to the normal 
control group (G1), and was found to be safe with respect to 
the body weight, feed intake, and most of the vital organs 
toxicity as compared to the normal control (G1). 
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Table 4. Effect of administration of the test formulation on the relative organ weight ratio (percentage) of various vital organs in female Sprague Dawley rats. 
Relative organ weight (%) G1 G2 G3 G4 G5 G6 
Liver 3.11 ± 0.13 3.25 ± 0.13 3.85 ± 0.06 3.47 ± 0.08 4.02 ± 0.10 3.19 ± 0.07 
Lungs 0.64 ± 0.02 0.73 ± 0.03 0.71 ± 0.03 0.68 ± 0.03 0.77 ± 0.02 0.75 ± 0.02 
Kidneys 0.75 ± 0.03 0.82 ± 0.02 0.79 ± 0.01 0.80 ± 0.02 0.86 ± 0.02 0.84 ± 0.03 
Brain 0.84 ± 0.05 0.92 ± 0.03 0.83 ± 0.03 0.78 ± 0.03 0.92 ± 0.04 0.89 ± 0.04 
Heart 0.40 ± 0.02 0.44 ± 0.02 0.43 ± 0.01 0.41 ±0.02 0.49 ± 0.02 0.44 ± 0.03 
Eyes 0.11 ± 0.01 0.12 ± 0.01 0.11 ± 0.01 0.10 ± 0.01 0.19 ± 0.07 0.11 ± 0.01 
Spleen 0.31 ± 0.01 0.36 ± 0.02 0.33 ± 0.01 0.31 ± 0.02 0.34 ± 0.03 0.34 ± 0.01 
Whole intestine 6.25 ± 0.20 6.73 ± 0.21 9.01 ± 0.49 8.90 ± 0.50 7.39 ± 0.27 6.73 ± 0.27 
Ovaries 0.08 ± 0.01 0.10 ± 0.01 0.09 ± 0.01 0.09 ± 0.01 0.09 ±0.01 0.08 ± 0.00 
G1: Normal control; G2: Disease control; G3: Biofield Energy Treated test formulation; G4: Untreated test formulation; G5: Reference item (Levamisole); G6: 
Biofield Energy Treated group per se at day -15. 
The organ to body weight ratio is a useful index for the 
identification of swelling, atrophy or hypertrophy [48]. The 
increase in body weight or organ weight with the exposure of 
any compound in the animals during experiment suggested the 
hypertrophy, while decrease in the relative weight indicated the 
atrophy. The increase in body weight and organ to body weight 
ratio might be correlated with the sign of product toxicity, but 
the experimental results suggested that there was not much 
change in most of the vital organs, which depicts that the test 
product was non-toxic to the animals throughout the exposure 
period (22 days) at the dose of 1105.005 mg/kg. 
3.6. Assessment of Gross and Histopathological 
Examination 
The effect of the Biofield Energy Treatment on 
herbomineral formulation on histopathological findings in 
female rats is shown in the Figure 2. No significant 
differences were observed either in gross or microscopic 
observation of the tested organs. Histopathological study 
results also suggest that no treatment-related 
histopathological findings were reported in all the 
experimental animals as compared to the control group. The 
detailed histopathological images of microscopic sections of 
the organs are presented in the Figure 2. Mild vacuolization 
in centrizonal hepatocytes was observed in few animals in 
the untreated test formulation group (G4; 3/6). Scattered 
hepatocytic vacuolation was observed in few animals in the 
normal control (G1; 2/6) and disease control (G2; 1/6) 
groups. All other organs of animals were devoid of any 
microscopic changes (Figure 2). 
 
Figure 2. Histopathological photomicrograph of major organs tested after the Biofield Energy Treated test formulation for consecutive 22 days in female 
Sprague Dawley rats. All the tissues were sectioned transversely and stained with hematoxylin (H) and eosin (E). G1: Normal control; G2: Disease control; 
G3: Biofield Energy Treated test formulation; G4: Untreated test formulation; G5: Reference item (Levamisole); G6: Biofield Energy Treated group per se at 
day -15. 
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Biofield Energy Healing has been reported to be effective 
in cancer treatment by reducing the level of cytokines [49]. 
The National Center for Complementary/Alternative 
Medicine (NCCAM,) 34% of adults in U.S. populations 
depends on some forms of complementary health approach, 
among which energy medicine is one of them. About 80% of 
the world population depends upon the traditional medicine 
for health benefits in the developing world [50]. 
Complementary and Alternative Medicine (CAM) has 
several advantages instead of the current preferred treatment 
approach [51]. Biofield Energy Treated herbomineral 
formulation might act as better immunomodulatory medicine 
in the near future due to its anti-inflammatory and 
immunomodulatory effects. Therefore, it is assumed that the 
Biofield Energy Treated herbomineral formulation might be 
considered as a safe dietary supplement for boosting the 
immune response. 
4. Conclusions 
The primary antibody titre level was significantly (p≤0.05) 
increased by 185.88% in the Biofield Energy Treated test 
formulation group (G3) as compared to the disease control 
group (G2) and also showed better results than the untreated 
test formulation group (G4). The secondary antibody titre 
level was significantly (p≤0.001) increased by 540% in the 
G3 group as compared to the G2 group. Moreover, the 
secondary antibody titre level was also increased 
significantly (p≤0.05) by 193% in the Biofield Energy 
Treated group per se at day -15 (G6), as compared to the G2 
group. The paw volume data showed an alteration in the G3 
and G6 groups as compared to the G2 group. The level of 
magnesium was increased by 9.31% in the G3 group as 
compared to the G2 group. The platelet count was 
significantly increased by 11.16% in the G3 group as 
compared to the G2 group. Uric acid level was significantly 
decreased by 23.88% in the G3 group as compared to the G2 
group. The Biofield Energy Treated herbomineral 
formulation did not show any sign of toxicity as evidenced 
by clinical signs and mortality. Further, no treatment-related 
changes were observed in the Biofield Energy Treated test 
formulation group with respect to the body weight and feed 
consumption during the experiment. The percentage of organ 
to body weight ratio data suggested that the Biofield Energy 
Treated test formulation was found to be safe with respect to 
the most of the vital organs toxicity. Overall, the Biofield 
Energy Treated herbomineral formulation showed better 
immune response without producing any toxicity as 
compared with the untreated test formulation. Thus, The 
Trivedi Effect
®
 - Biofield Energy Healing has the significant 
capability to alter the immunomodulatory activity of the 
herbomineral formulation in female Sprague Dawley rats. It 
is then anticipitated that the Biofield Energy Treated 
herbomineral formulation and Biofield Energy Treatment 
group per se could be a more useful as immunomodulatory 
formulation for healthy human and in patients in the near 
future. Besides, it can also be utilized in organ transplants 
(for example kidney transplants, liver transplants and heart 
transplants), various autoimmune disorders such as Lupus, 
Addison Disease, Celiac Disease (gluten-sensitive 
enteropathy), Dermatomyositis, Graves’ Disease, Hashimoto 
Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, 
Pernicious Anemia, Aplastic Anemia, Reactive Arthritis, 
Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus 
Erythematosus, Type 1 Diabetes, Alopecia Areata, Crohn’s 
Disease, Fibromyalgia, Vitiligo, Psoriasis, Scleroderma, 
Chronic Fatigue Syndrome and Vasculitis, as well as 
inflammatory disorders such as Asthma, Ulcerative Colitis, 
Alzheimer’s Disease, Atherosclerosis, Dermatitis, 
Diverticulitis, Hepatitis, Irritable Bowel Syndrome, 
Parkinson’s Disease and stress etc. to modulate the immune 
system by improving overall health. 
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